Healthcare Industry News:  BD  

Biopharmaceuticals

 News Release - November 28, 2007

Synthetic Blood Announces VCURES Receives $1.3 Million From U.S. Navy for Decompression Sickness Research with Oxycyte

COSTA MESA, Calif.--(HSMN NewsFeed)--Synthetic Blood International, Inc. (OTCBB:SYBD ), a biopharmaceutical company, today announced that Virginia Commonwealth University Reanimation Engineering Shock Center (VCURES) has received $1.3 million under a previously awarded U.S. Office of Naval Research grant for the treatment and prevention of decompression sickness (DCS) with Oxycyte™. Oxycyte is Synthetic Blood’s proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute. Synthetic Blood has begun the process of manufacturing and shipping Oxycyte to VCURES for use in these studies.

DCS occurs when a diver or submarine ascends to the water’s surface too quickly, and nitrogen gas that was dissolved in blood forms bubbles that clog blood vessels that supply oxygen to the heart and central nervous system. This can result in massive stroke, paralysis and death.

Work under the grant, titled “Coordinated Follow-up Studies in the Treatment and Prevention of Decompression Illness and Venous Air Embolisms with Perfluorocarbon Emulsions,” is led by Bruce Spiess, M.D., Virginia Commonwealth University Professor and Vice-Chairman of Anesthesiology, Chief of Cardiothoracic Anesthesia and Director of the Research Department of Anesthesiology.

“Oxycyte has proven capability to carry significantly more nitrogen and oxygen than plasma. Our planned DCS studies will build upon this current knowledge-base, and will focus on the use of mixtures of helium and oxygen to determine Oxycyte’s effectiveness in carrying and eliminating nitrogen prior to emergency surfacing while preserving oxygen delivery to vital tissues,” said Dr. Spiess. “These studies also will advance our understanding of the potential therapeutic benefits of Oxycyte for use in multiple states of critical illness and injury, including traumatic brain injury (TBI).”

Robert Larsen, Interim President and CEO of Synthetic Blood, said, “We are pleased that the work by Dr. Spiess with Oxycyte has led the U.S. Navy to this priority effort in making submarine operations safer for its personnel. Oxycyte has shown great promise as a safe and effective oxygen carrier and blood substitute, with many potential therapeutic applications. In addition to DCS, we are actively pursuing research with Oxycyte in TBI and continue to work with Dr. Spiess and VCURES to advance Oxycyte through later-stage clinical trials. In conjunction with VCURES, subject to U.S. Food and Drug Administration approval, we are planning a 100- to 150-patient, double-blind, multi-center, placebo-controlled Phase IIb study to compare Oxycyte with present-day advanced therapies in TBI.”

About Synthetic Blood International

Synthetic Blood International is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a blood substitute and a liquid ventilation product, and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs, and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, visit www.sybd.com.

Safe Harbor Statement The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward looking information made on the Company’s behalf. All statements other than statements of historical facts which address the Company’s expectations of source of capital or which express the Company’s expectation for the future with respect to financial performance or operating strategies, can be identified as forward-looking statements. Such statements made by the Company are based on knowledge of the environment in which it operates, but because of the factors previously listed, as well as other factors beyond the control of the Company, actual results may differ materially from the expectations expressed in the forward-looking statements.


Source: Synthetic Blood International

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.